The effect of etanercept on hyperalgesia in neuropathic pain rats

Objective: To investigate the effect of recombinant human tumor necrosis factor receptor type Ⅱ-antibody fusion protein(etanercept)on hyperalgesia in neuropathic pain(CCI)rats.Methods: Thirty-two adult male SD rats were selected and randomly divided into four groups,which included sham-operation group,chronic constriction injury(CCI) group,0.4 mg/kg etanercept group and 0.8 mg/kg etanercept group.CCI group and etanercept groups were establish CCI model according to the method of Bennett.Etanercept groups given daily subcutaneous injection of 0.4 mg/kg or 0.8 mg/kg etanercept from the immediate postoperative to sampling point,and sham-operation group and CCI group given subcutaneous injection of saline at same volume.Measure the mechanical withdrawal threshold(MWT),the thermal withdrawal latency(TWL)and the motor function score in preoperative 1 d,postoperative 1 d,postoperative 3 d,postoperative 7 d respectively.Results: Compared with sham-operation group,the postoperative 1 d,postoperative 3 d,postoperative 7 d of MWT and TWL in CCI group have significantly decreased(P0.05).Compared with CCI group,at each time point after operation,the MWT and TWL of etanercept group have significantly elevated(P0.05),and the high-dose group increased more significantly than the low-dose group(P0.05).Conclusion: Etanercept can inhibit hyperalgesia response induced by CCI,and high-dose more effectively than low-dose.